1. Home
  2. BLRX

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Founded: 2003 Country:
Israel
Israel
Employees: N/A City: N/A
Market Cap: 17.1M IPO Year: 2011
Target Price: $19.00 AVG Volume (30 days): 52.2K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.00 EPS Growth: N/A
52 Week Low/High: $2.30 - $22.60 Next Earning Date: 11-24-2025
Revenue: $17,251,000 Revenue Growth: 1.19%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

BLRX Daily Stock ML Predictions

Share on Social Networks: